peptidase comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-02-24. Where a claim depends on a specific study, the study is described rather than over-claimed.
Animal studies have examined behaviour in tests of anxiety, memory retention and stress response, and several report changes in neurotrophic or neurotransmitter-related markers. The human evidence base is much smaller, consisting mainly of short trials conducted in Russia with limited reporting in English-language journals. Sample sizes are modest and outcome measures vary between studies, so the findings are best described as preliminary. Independent replication under modern trial standards has not been widely reported.
Outside its country of origin the compound is generally handled as a research chemical rather than an approved medicine. No regulatory approval from the United States Food and Drug Administration or the European Medicines Agency has been granted for human use. Identity and purity are normally checked by reverse-phase high-performance liquid chromatography, with mass spectrometry used to confirm the molecular mass. Lyophilised material is stored cold and desiccated, and repeated freeze-thaw cycles are avoided.
Proposed mechanisms center on modulation of the GABA system, but no single molecular target has been confirmed. Rodent studies report changes in GABA-A receptor expression and in the turnover of serotonin, dopamine, and norepinephrine in several brain regions. Increases in brain-derived neurotrophic factor and its receptor have also been described after repeated administration. These findings come largely from animal models, and the degree to which they describe human neurochemistry remains an open question. The mechanism is best characterized as multi-system and not fully resolved.
Pharmacokinetic data are limited. Like most short peptides, Selank is vulnerable to plasma and tissue peptidases, and its measured half-life in circulation is short, on a minutes scale. The Pro-Gly-Pro tail slows this degradation but does not eliminate it. Intranasal administration is the route described in most reports, with absorption through the nasal mucosa and a hypothesized path into the central nervous system that avoids the blood-brain barrier. Direct measurements of human brain exposure are unavailable, so distribution claims rest on inference from animal work.
| Property | Value | Notes |
|---|---|---|
| Common route | Intranasal | Also injected in some animal work |
| Solubility class | Freely soluble in water | Solid form is hygroscopic |
| Typical storage | About -20 degrees Celsius | Keep desiccated and dark |
| Purity method | Reverse-phase HPLC | Reported as area percent |
| Confirmatory method | Mass spectrometry | Verifies expected molecular mass |
Selank is studied chiefly as an animal-model anxiolytic with proposed secondary effects on memory and immune signaling. Reported mechanisms include modulation of the GABA-A receptor complex, inhibition of enkephalin-degrading enzymes, and shifts in monoamine turnover within limbic structures. Some experiments describe increased expression of brain-derived neurotrophic factor in the hippocampus after repeated dosing. No single molecular target has been confirmed, and the peptide does not bind any receptor with the selectivity typical of a conventional small-molecule drug. Mechanism therefore remains a set of hypotheses rather than an established pathway.
Laboratory work relies on standard behavioral paradigms. Rodents are tested in the elevated plus maze, open field, and passive avoidance tasks, with outcomes compared against diazepam or vehicle controls. Intranasal dosing is used most often because it bypasses first-pass metabolism, though intraperitoneal and intravenous routes also appear in published protocols. Biochemical endpoints include tissue BDNF concentrations, cytokine levels, and monoamine metabolites. Human data are limited to small Russian trials reporting reduced anxiety scores; most were not prospectively registered, and few employed independent outcome assessment.
Measuring peptide exposure inside the brain is technically difficult. Selank is degraded rapidly in plasma, and assays must separate intact peptide from fragments, which favors targeted mass spectrometry over immunoassays alone. Reported half-lives are short, on the order of minutes, so effects observed hours later are attributed to downstream signaling rather than to the parent compound. Blood-brain barrier permeability is debated and rarely quantified directly. Gaps include absent dose-response characterization, inconsistent reporting of purity, and almost no pharmacokinetic data from human participants.
Selank is a synthetic heptapeptide developed in Russia during the 1990s. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences designed it as a stabilized analog of tuftsin, a naturally occurring immunomodulatory tetrapeptide. The compound has been studied primarily for its reported anxiolytic and nootropic effects. It remains largely unknown in Western pharmacology and is not approved as a medicine by major regulators such as the FDA or the EMA.
The primary structure of Selank is Thr-Lys-Pro-Arg-Pro-Gly-Pro, corresponding to the molecular formula C33H57N11O9 and a monoisotopic mass of roughly 751.9 daltons. The N-terminal threonine and the arginine residue in the fourth position are shared with tuftsin, which carries the sequence Thr-Lys-Pro-Arg. The three additional residues at the C-terminus, Pro-Gly-Pro, extend the chain and are associated with greater resistance to enzymatic degradation. This extension also separates Selank from the shorter parent peptide.
Proposed mechanisms centre on the GABAergic system. Animal and tissue studies report changes in GABA-A receptor expression and reduced activity of GABA transaminase, the enzyme that degrades GABA. Effects on monoamine turnover, including serotonin and dopamine pathways, are also described, and a separate line of work links the peptide to increased expression of brain-derived neurotrophic factor in hippocampal tissue. Most of these findings come from rodent models and cell preparations. How the individual observations combine into a single coherent mode of action is not settled.
Pharmacokinetic data are sparse and largely derived from animal work. After intranasal administration the peptide appears in plasma within minutes, and reported half-lives are short, on the order of minutes to tens of minutes. Degradation proceeds through ordinary proteolytic cleavage into constituent amino acids and smaller fragments. Direct evidence that intact Selank reaches brain tissue in meaningful amounts is limited, and the extent of blood-brain barrier penetration is debated. Some authors argue that fragments, not the parent peptide, carry much of the observed activity.
==== Rosacea ==== Rosacea is a chronic skin disorder that presents with recurrent flushing, erythema, papules, and telangiectasia. Methyl aminolevulinate (MAL) is a drug used as a photosensitizer in photodynamic therapy like LEDT. The red-light MAL-LED therapy performed significant therapeutic effects on the recovery of papulopustular lesions in an in-vivo clinical trial conducted with rosacea patients. A more recent study proves the in-vitro effect of LEDT at wavelengths of 630 nm and 940 nm in rosacea-like mouse skin.
=== The JGRB and the Representative Body for Sergeants and Inspectors === From 1927 to 1962, Garda members were represented for limited purposes by a Joint Garda Representative Body (JGRB); this body was criticised as dominated by senior officers and unable to secure needed changes in conditions of work. After a major and unauthorised meeting of hundreds of rank-and-file Gardaí at the Macushla Ballroom in Dublin, a chain of events led to the establishment by the then Minister for Justice, Charles Haughey, of three new representative bodies, divided by rank, including the Representative Body for Inspectors, Station Sergeants and Sergeants (RBISS). That body was permitted to appoint a sergeant, on secondment, as its part-time general secretary. It was also permitted to apply to the Garda Commissioner for permission to request a subscription from members. The three bodies could, and were required to if requested by the Garda Commissioner, form a temporary joint representative body. There was cooperation at other levels too, with the magazine The Garda Review being issued by the GRA and AGSI together.
=== April === 1 April It is reported that three British men are being held in custody by the Taliban in Afghanistan. Manchester becomes the first city in the UK to launch a tourist tax, with a £1-per room per night City Visitor Charge. 2 April Home Secretary Suella Braverman confirms the UK is in negotiations with the Taliban following the reported arrest of three British nationals in Afghanistan. Braverman says that Rwanda is a safe place for the UK to send refugees after being asked about refugees being shot there by police at a demonstration in 2018, saying "that might be 2018, we're looking at 2023 and beyond". 3 April Members of the Public and Commercial Services Union working at the Passport Office begin a five-week strike over pay and conditions. The National Education Union announces two further strike dates in England on 27 April and 2 May, stating that the offer from the pay UK government is unacceptable, not fully funded, and does not address a shortage of teachers. The cost of a first class stamp increases by 15p to £1.10, and a second class stamp by 7p to 75p. Thomas Cashman is sentenced at Manchester Crown Court to life imprisonment with a minimum term of 42 years for the murder of Olivia Pratt-Korbel, meaning he will be in his mid-70s before becoming eligible for parole. 4 April Royal Mail issue new stamps featuring King Charles III, with an increase of a first class stamp up by 15p to £1.10, while the cost of a second class stamp has risen by 7p to 75p.
Sources: en.wikipedia.org
== See also == American Society of Anesthesiologists Anesthetic technician – Type of healthcare professional Nurse anesthetist – Advanced Practice Registered Nurse with expertise in anesthesia Local anesthetic – Medications to reversibly block pain Neuromuscular-blocking drug – Type of paralyzing anesthetic including lepto- and pachycurares
=== Nomenclature === The nomenclature of modified GFPs is often confusing due to overlapping mapping of several GFP versions onto a single name. For example, mGFP often refers to a GFP with an N-terminal palmitoylation that causes the GFP to bind to cell membranes. However, the same term is also used to refer to monomeric GFP, which is often achieved by the dimer interface breaking A206K mutation. Wild-type GFP has a weak dimerization tendency at concentrations above 5 mg/mL. mGFP also stands for "modified GFP", which has been optimized through amino acid exchange for stable expression in plant cells.
== Plasma proteins for clinical use == Many of the proteins in plasma have important therapeutic uses. Albumin is commonly used to replenish and maintain blood volume after traumatic injury, during surgery, and during plasma exchange. Since albumin is the most abundant protein in the plasma its use may be the most well known, but many other proteins, although present in low concentrations, can have important clinical uses. See table below.
Sources: en.wikipedia.org
Most published work uses intranasal application, either as drops or as a nasal spray. Injection routes appear in a smaller set of animal experiments. Oral use is uncommon in the literature because peptide breakdown and poor absorption limit this route.
Reported human trials are few, brief and originate mainly from one country. They describe effects on anxiety-related measures, but sample sizes are small and reporting is limited. The results are widely regarded as preliminary rather than confirmed.
Reverse-phase liquid chromatography is used to assess purity and separation of related impurities. Mass spectrometry confirms that the observed molecular mass matches the expected peptide. A certificate of analysis from the supplier is the usual document of record.
Reports describe effects on GABA-A receptor expression, monoamine turnover, and neurotrophic factor levels. These are proposed mechanisms drawn mainly from animal models. No single molecular target has been established.